ZENITH HEALTH CARE LTD. (ZENITHHE) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of ZENITH HEALTH CARE LTD. ₹1.91, price ₹3.15, upside -39.4%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ZENITH HEALTH CARE LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹2.42 – ₹11.20 · fair‑value band ₹0.9600 – ₹1.91 · the ₹3.15 price screens above the ₹1.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ZENITH HEALTH CARE in your weekly email
Every Wednesday you see whether ZENITH HEALTH CARE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zenith Healthcare Limited manufactures, sells, and exports pharmaceutical formulations in India. The company offers products in the form of tablets, capsules, oral liquids, and injections in various therapeutic areas. It also engages in the contract manufacturing of various dosage forms.
Show more
Zenith Healthcare Limited manufactures, sells, and exports pharmaceutical formulations in India. The company offers products in the form of tablets, capsules, oral liquids, and injections in various therapeutic areas. It also engages in the contract manufacturing of various dosage forms. The company also supplies medicines to Cambodia, Myanmar, Papa New Guinea, Sri Lanka, Kenya, Nigeria, Gambia, Zambia, Namibia, Botswana, Armenia, Georgia, Uzbekistan, Paraguay, Bolivia, Venezuela, Guatemala, Barbados, Jamaica, Bahamas, Yemen, and Turkey. Zenith Healthcare Limited was founded in 1994 and is based in Ahmedabad, India.
Stock analysis
ZENITH HEALTH CARE LTD. (ZENITHHE) currently trades at ₹3.15, while our model-based Fair Value estimate is ₹1.91, 39.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹0.9300 per share, and 0 of the 10 models we run sit above the ₹3.15 price.
Bear case: the DCF Models group reads lowest at ₹0.4300, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹0.9600 (bear) to ₹1.91 (bull), the price of ₹3.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
ZENITH HEALTH CARE LTD. reported revenue of ₹105M in FY2026 versus ₹224M in FY2022, a compound −17.2%/yr. Reported net income was ₹51.0K in FY2026, compounding −64.2%/yr from FY2022.
Key figures
Market cap ₹169M (≈ $1.8M) · P/S ratio 1.58 · Net margin 0.0% · Return on equity 0.1% · Return on assets (EBIT) −0.1% · Operating margin −19.8% · Revenue (TTM) ₹105M · Revenue growth (YoY) −24.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −39%, ZENITHHE screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹0.0100 to ₹0.9300). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹0.9600Fair Value ₹1.91Bull ₹1.91
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2021 (pandemic). Over 10 years: +11.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−59.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−59.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → −4%
Compare ZENITH HEALTH CARE LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−39.0% · Below median
Profitability
Return on equity (TTM)0.1% · Below median
Return on assets−2.2% · Bottom 25%
Net margin (TTM)0.1% · Below median
Operating margin (TTM)−19.8% · Bottom 25%
Growth and dividend
Revenue growth−24.8% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 26
PAST (return on equity)0· sector 29
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ZENITH HEALTH CARE LTD. Fair Value". https://www.fairvalue-calculator.com/stock/ZENITHHE
Frequently asked questions
Is ZENITH HEALTH CARE LTD. (ZENITHHE) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹1.91 versus a price of ₹3.15, about −39% upside (overvalued).
What is the fair value of ZENITHHE?
Our model-based fair value for ZENITH HEALTH CARE LTD. is ₹1.91 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹3.15.
What is the quality score of ZENITHHE?
ZENITH HEALTH CARE LTD. has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ZENITH HEALTH CARE LTD. (ZENITHHE)?
Our model-based price target is the fair value of ₹1.91 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario ₹0.9600, optimistic scenario ₹1.91. It is a calculation from audited fundamentals, not an analyst target.
What is the ZENITH HEALTH CARE LTD. stock forecast for 2026?
Our models put fair value at ₹1.91, about −39% upside versus a price of ₹3.15 (overvalued). Cautious scenario ₹0.9600, optimistic scenario ₹1.91. The calculation is refreshed regularly with new filings.
What is the revenue of ZENITH HEALTH CARE LTD. (ZENITHHE)?
ZENITH HEALTH CARE LTD. reported trailing-twelve-month revenue of about ₹105M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ZENITH HEALTH CARE LTD. (ZENITHHE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ZENITH HEALTH CARE LTD. it is ₹1.91 per share (as of Sep 24, 2026), against a price of ₹3.15. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is ZENITH HEALTH CARE LTD. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ZENITHHE trades above its calculated fair value: price ₹3.15, fair value ₹1.91, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZENITHHE?
No. The price is what the market pays today (₹3.15); the fair value is what the company's own numbers justify (₹1.91). For ZENITH HEALTH CARE LTD. the two are ₹1.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is ZENITH HEALTH CARE LTD. worth?
The market values ZENITH HEALTH CARE LTD. at about ₹169M (market capitalisation, as of Sep 24, 2026). Per share that is ₹3.15; our models calculate a fair value of ₹1.91 per share.
What do the bullish and bearish scenarios say about ZENITHHE?
Our models span a range for ZENITH HEALTH CARE LTD.: cautious scenario ₹0.9600, base ₹1.91, optimistic ₹1.91 per share (as of Sep 24, 2026, price ₹3.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ZENITH HEALTH CARE LTD. (ZENITHHE)?
Balance-sheet figures for ZENITH HEALTH CARE LTD. (as of Sep 24, 2026): return on equity 0.1%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is ZENITHHE from its 52-week high?
ZENITH HEALTH CARE LTD. trades at ₹3.15, about 25% below its 52-week high of ₹4.21 and 30% above the low of ₹2.42 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1.91 is for.
Which stocks are comparable to ZENITH HEALTH CARE LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ZENITH HEALTH CARE LTD. stock attractive at the current price?
The data as of Sep 24, 2026: price ₹3.15, calculated fair value ₹1.91 (−39%), Quality Score 51/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZENITHHE calculated?
We run ZENITH HEALTH CARE LTD. through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1.91, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ZENITH HEALTH CARE LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The closing price on Oct 1, 2026 was ₹3.15. Our model-based fair value is ₹1.91, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ZENITH HEALTH CARE LTD. right now?
The price sits above even our optimistic bull case (₹1.91). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹0.9600 to ₹1.91) leaves room in how you read the outcome.
Key figures of ZENITH HEALTH CARE LTD.
How large is the market capitalisation of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The market capitalisation of ZENITH HEALTH CARE LTD. is ₹169M (≈ $1.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The price-to-sales ratio of ZENITH HEALTH CARE LTD. is 1.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The net margin of ZENITH HEALTH CARE LTD. is 0.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The return on equity (ROE) of ZENITH HEALTH CARE LTD. is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ZENITH HEALTH CARE LTD. (ZENITHHE)?
On an EBIT basis the return on assets of ZENITH HEALTH CARE LTD. is −0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ZENITH HEALTH CARE LTD. (ZENITHHE)?
The operating margin of ZENITH HEALTH CARE LTD. is −19.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ZENITH HEALTH CARE LTD. (ZENITHHE)?
Revenue at ZENITH HEALTH CARE LTD. is growing −24.8% versus a year earlier (3y avg −7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ZENITH HEALTH CARE LTD. (ZENITHHE)?
Earnings per share at ZENITH HEALTH CARE LTD. are growing +52.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ZENITH HEALTH CARE LTD. (ZENITHHE) generate?
The free cash flow of ZENITH HEALTH CARE LTD. is −₹9.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch ZENITH HEALTH CARE LTD. in the live analysis
One click puts ZENITH HEALTH CARE LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
